In December 2024, Russia’s Ministry of Health announced the development of a therapeutic cancer vaccine, which will be made available free of charge in the country’s public health system from 2025. The vaccine, developed by the Gamaleya National Research Centre, uses messenger RNA (mRNA) technology and relies on a personalised approach to treat different types of tumour.
Innovation and aim
The new vaccine is based on the genetic analysis of each patient’s tumours, allowing a tailored formulation that instructs the immune system to identify and fight cancer cells. According to Alexander Gintsburg, director of the Gamaleya Centre, the immunisation can suppress tumour growth and prevent the spread of cancer.
Another innovation in the spotlight is the EnteroMix vaccine, which combines four non-pathogenic viruses capable of destroying malignant cells and stimulating the immune system. This second vaccine is still being prepared for clinical trials, which are expected to begin in late 2024 or early 2025.
Challenges and scepticism
Despite the enthusiasm generated, the scientific community remains reserved about the efficacy and safety of these vaccines. To date, no details of clinical trials or results published in scientific journals have been presented. It is also not known which specific types of cancer the vaccines could treat.
Although other countries, such as the United States and the United Kingdom, are also developing personalised cancer treatments, the Russian announcement places the country in a central position in the search for innovative solutions. However, practical implementation will depend on concrete results and scientific validation in the coming months.
With expectations high, the world awaits more information about this promised revolution in cancer treatment.
